Follow-on biologics in oncology – the need for global and local regulations
<br>[Polish version: Leki bionastępcze w onkologii – potrzeba globalnych i lokalnych regulacji p. 467]

Iwona Hus

doi:10.5114/wo.2012.32475

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2012
vol. 16

Send email

Copy url:

abstract:

Review paper

Follow-on biologics in oncology – the need for global and local regulations
[Polish version: Leki bionastępcze w onkologii – potrzeba globalnych i lokalnych regulacji p. 467]

Iwona Hus

Wspolczesna Onkol 2012; 16 (6): 461–466
[Polish version: Wspolczesna Onkol 2012; 16 (6): 467–473]

DOI: https://doi.org/10.5114/wo.2012.32475

Online publish date: 2013/01/04

View full text Get citation

PlumX metrics:

The patent expiration for first-generation biological drugs has prompted the development of a new group of biopharmaceuticals – follow-on biologics. The extent of studies needed in the process of follow-on biologics approval is incomparably greater than in the case of generics but reduced in comparison to innovative biologics. The basis for the approval is to show the similarity sufficient to ensure the same quality, safety and efficacy as the reference medicine. In oncology, the most widely used among so far registered follow-on biologics are biosimilar granulocyte colony-stimulating factors, and in the hitherto clinical practice, there have been no concerns about their effectiveness and safety. It is expected that along with the patent expiry of next biologics, the number of follow-on biologics will increasingly grow, that implies the need to develop and implement specific regulations for this new class of medicine.

keywords:

Follow-on biologics in oncology – the need for global and local regulations [Polish version: Leki bionastępcze w onkologii – potrzeba globalnych i lokalnych regulacji p. 467]

Iwona Hus

follow-on biologics, granulocyte colony-stimulating factors, oncology

Follow-on biologics in oncology – the need for global and local regulations
[Polish version: Leki bionastępcze w onkologii – potrzeba globalnych i lokalnych regulacji p. 467]